Cereno Scientific Ab Class B · OMXSTO:CRNO_B
Cereno Scientific Ab Class B — Nordic Health Summit Japan 2026
9 slides from Cereno Scientific Ab Class B's conference presentation, Apr 24, 2026
Slide 1: Ahead of the Curve – Changing the Treatment Paradigm of Cardiopulmonary Diseases
Ahead of the Curve – Changing the Treatment Paradigm of Cardiopulmonary Diseases Sten R. Sörensen, CEO and Board Member Corporate presentation for Nordic Health Summit Japan 24th April 2026
Slide 2: Cereno changing the treatment paradigm of cardiopulmonary diseases
Cereno changing the treatment paradigm of cardiopulmonary diseases Founded at University of Gothenburg, Sweden, in 2012 HQ: Sweden (Gothenburg), Subsidiary in Boston Novel approach HDAC inhibition through epigenetic modulation – disease-modification potential Leadership experienced in biotech, pharm
Slide 3: HDACi Platform
HDACi Platform Epigenetic Modulation through HDAC inhibition target core pathological drivers of cardiovascular and pulmonary disease Cereno's Class I HDAC Inhibitor Platform Addresses the four core pathological drivers Targets histone modification Vascular Remodeling Reverses structural changes in
Slide 4: HDACi First-in-class Pipeline
HDACi First-in-class Pipeline Cereno Scientific continues to advance its HDACi clinical pipeline towards major milestones Initial Focus – Rare and Orphan Diseases CS1 Pulmonary Arterial Hypertension (PAH) Initiating Phase IIb in Q2 2026 Proprietary oral reformulation of VPA Class I HDACi CS014 Pulmo
Slide 5: CS1 – once daily oral therapy aims to slow, halt and reverse PAH disease progression
CS1 CS1 – once daily oral therapy aims to slow, halt and reverse PAH disease progression Preclinical & clinical results consistent Pathological vascular remodeling in PAH with signals of reverse remodeling PAH Progression Phase IIa results • Good safety and tolerability profile • Efficacy signals :
Slide 6: Platform Value
Platform Value Epigenetic HDAC inhibitor platform is applicable in multiple diseases addressing shared pathological pathways Cereno’s initial focus in rare and orphan disease Scalable platform to multiple diseases CS1 CS014 CS014 4,000,000+ 3,500,000+ 2,000,000+ Estimated 1,400,000+ addressable pati
Slide 7: Advancing HDACi-based epigenetic modulation platform for cardiopulmonary diseases
Advancing HDACi-based epigenetic modulation platform for cardiopulmonary diseases At a glance External confidence and recognition of value proposition • Validated Platform, Late-Stage Assets, Large Market Scientific Validation • Targets vascular remodeling, fibrosis, inflammation, thrombosis >37 res
Slide 8: Cereno Scientific is pioneering a paradigm shift in cardiopulmonary disease, from managing symptoms to
Cereno Scientific is pioneering a paradigm shift in cardiopulmonary disease, from managing symptoms to modifying the disease itself, through a uniquely positioned epigenetic HDAC inhibitor platform. 8
Slide 9: Cereno Scientific is pioneering treatments to enhance and extend life
Cereno Scientific is pioneering treatments to enhance and extend life. The innovative company’s pipeline innovative offers pipeline disease- offers disease-modifying modifying drug candidates drug candidates to empower to empower people suffering people suffering from rare from cardiovascular rare c